JP2014513046A5 - - Google Patents

Download PDF

Info

Publication number
JP2014513046A5
JP2014513046A5 JP2013553647A JP2013553647A JP2014513046A5 JP 2014513046 A5 JP2014513046 A5 JP 2014513046A5 JP 2013553647 A JP2013553647 A JP 2013553647A JP 2013553647 A JP2013553647 A JP 2013553647A JP 2014513046 A5 JP2014513046 A5 JP 2014513046A5
Authority
JP
Japan
Prior art keywords
deuterium
alkyl
cycloalkyl
compound
phenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2013553647A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014513046A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2012/024974 external-priority patent/WO2012112492A1/en
Publication of JP2014513046A publication Critical patent/JP2014513046A/ja
Publication of JP2014513046A5 publication Critical patent/JP2014513046A5/ja
Pending legal-status Critical Current

Links

JP2013553647A 2011-02-14 2012-02-14 4−ヒドロキシ酪酸の重水素化類似体 Pending JP2014513046A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161442451P 2011-02-14 2011-02-14
US61/442,451 2011-02-14
US201161484296P 2011-05-10 2011-05-10
US61/484,296 2011-05-10
PCT/US2012/024974 WO2012112492A1 (en) 2011-02-14 2012-02-14 4-hydroxybutyric acid deuterated analogs

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2017083295A Division JP6692319B2 (ja) 2011-02-14 2017-04-20 4−ヒドロキシ酪酸の重水素化類似体

Publications (2)

Publication Number Publication Date
JP2014513046A JP2014513046A (ja) 2014-05-29
JP2014513046A5 true JP2014513046A5 (https=) 2015-04-02

Family

ID=46672903

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2013553647A Pending JP2014513046A (ja) 2011-02-14 2012-02-14 4−ヒドロキシ酪酸の重水素化類似体
JP2017083295A Active JP6692319B2 (ja) 2011-02-14 2017-04-20 4−ヒドロキシ酪酸の重水素化類似体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2017083295A Active JP6692319B2 (ja) 2011-02-14 2017-04-20 4−ヒドロキシ酪酸の重水素化類似体

Country Status (10)

Country Link
US (5) US8759394B2 (https=)
EP (1) EP2675771B1 (https=)
JP (2) JP2014513046A (https=)
KR (1) KR101976218B1 (https=)
CN (1) CN103370289B (https=)
BR (1) BR112013020620A2 (https=)
ES (1) ES2804540T3 (https=)
IL (1) IL227754B (https=)
MX (1) MX355742B (https=)
WO (1) WO2012112492A1 (https=)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2421808B1 (en) 2009-04-23 2013-07-31 Concert Pharmaceuticals Inc. 4-hydroxybutyric acid analogs
CA2794171C (en) 2010-03-24 2018-07-03 Jazz Pharmaceuticals, Inc. Controlled release dosage forms for high dose, water soluble and hygroscopic drug substances
KR101976218B1 (ko) 2011-02-14 2019-05-07 콘서트 파마슈티컬즈, 인크. 4-히드록시부티르산 중수소화 유사체
US10398662B1 (en) 2015-02-18 2019-09-03 Jazz Pharma Ireland Limited GHB formulation and method for its manufacture
CA2999367C (en) 2015-09-23 2023-09-26 Xw Laboratories Inc. Prodrugs of gamma-hydroxybutyric acid, compositions and uses thereof
CN108473411B (zh) * 2015-11-19 2022-08-12 协和发酵生化株式会社 3-羟基异戊酸的一价阳离子盐的晶体及该晶体的制造方法
CA3028608A1 (en) 2016-06-24 2017-12-28 Otsuka Pharmaceutical Factory, Inc. Crystal of amino acid salt of 3-hydroxyisovaleric acid and production method thereof
US11602513B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
UY37341A (es) 2016-07-22 2017-11-30 Flamel Ireland Ltd Formulaciones de gamma-hidroxibutirato de liberación modificada con farmacocinética mejorada
US11000498B2 (en) 2016-07-22 2021-05-11 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11504347B1 (en) 2016-07-22 2022-11-22 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11986451B1 (en) 2016-07-22 2024-05-21 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US12478604B1 (en) 2016-07-22 2025-11-25 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11602512B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US12186296B1 (en) 2016-07-22 2025-01-07 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US20180263936A1 (en) 2017-03-17 2018-09-20 Jazz Pharmaceuticals Ireland Limited Gamma-hydroxybutyrate compositions and their use for the treatment of disorders
EP3601235B1 (en) 2017-03-30 2026-03-04 XWPharma Ltd. Bicyclic heteroaryl derivatives, preparation and therapeutic uses thereof
AU2019239096A1 (en) * 2018-03-23 2020-08-27 Concert Pharmaceuticals, Inc. Deuterated analogs of D-beta-hydroxybutyric acid and uses thereof
CN114042070A (zh) 2018-09-30 2022-02-15 凯瑞康宁生物工程(武汉)有限公司 作为神经元组胺受体-3拮抗剂的化合物及其用途
CA3115122A1 (en) 2018-11-19 2020-05-28 Jazz Pharmaceuticals Ireland Limited Alcohol-resistant drug formulations
EP3930702A1 (en) 2019-03-01 2022-01-05 Flamel Ireland Limited Gamma-hydroxybutyrate compositions having improved pharmacokinetics in the fed state
TWI899126B (zh) 2019-12-20 2025-10-01 香港商凱瑞康寧有限公司 4-纈胺醯氧基丁酸的合成方法
TW202139986A (zh) * 2020-02-21 2021-11-01 愛爾蘭商爵士製藥愛爾蘭有限責任公司 治療原發性嗜睡症之方法
AU2021293941B2 (en) 2020-06-18 2024-03-28 XWPharma Ltd. Pharmaceutical granulations of water-soluble active pharmaceutical ingredients
CN115038432B (zh) 2020-06-18 2023-12-26 凯瑞康宁生物工程(武汉)有限公司 水溶性活性药物成分的控制释放制粒
WO2022020621A1 (en) 2020-07-24 2022-01-27 XWPharma Ltd. Pharmaceutical compositions and pharmacokinetics of a gamma-hydroxybutyric acid derivative
EP4225274A1 (en) 2020-10-05 2023-08-16 XWPharma Ltd. Modified release compositions of a gamma-hydroxybutyric acid derivative
WO2022076824A1 (en) 2020-10-08 2022-04-14 Jazz Pharmaceuticals Ireland Limited Sodium oxybate to treat idiopathic hypersomnia
JP2024511991A (ja) 2021-03-19 2024-03-18 エックスダブリューファーマ リミテッド ガンマ-ヒドロキシ酪酸誘導体の組み合わされた放出製剤の薬物動態
CN113200853A (zh) * 2021-05-19 2021-08-03 宁波窦氏化学科技有限公司 一种制备丁二酸二醇酯的工艺方法
US11779557B1 (en) 2022-02-07 2023-10-10 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11583510B1 (en) 2022-02-07 2023-02-21 Flamel Ireland Limited Methods of administering gamma hydroxybutyrate formulations after a high-fat meal
JP2026513019A (ja) 2023-02-03 2026-04-22 トリス・フアルマ・インコーポレーテツド 1晩1回の低ナトリウムオキシベート組成物
WO2025137671A1 (en) * 2023-12-22 2025-06-26 Temple University-Of The Commonwealth System Of Higher Education Short chain fatty acid compounds and uses thereof

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA814854B (en) * 1980-07-17 1982-07-28 J Klosa Nonhygroscopic salts of 4-hydroxybutryric acid, methods of their production and pharmaceutical preparations containing these salts
EP0044801B1 (de) 1980-07-17 1984-02-15 Josef Dr. Klosa Nichthygroskopische Salze der 4-Hydroxybuttersäure, Verfahren zu ihrer Herstellung und ihre Verwendung zur Herstellung pharmazeutischer Mittel
US4548716A (en) * 1984-07-25 1985-10-22 Lucas Boeve Method of producing ultrapure, pyrogen-free water
US4738985A (en) 1986-03-19 1988-04-19 The University Of Toronto Innovations Foundations Pharmaceutical composition and treatment
JP2727008B2 (ja) * 1989-02-01 1998-03-11 日本酸素株式会社 静菌化水の製造方法
DE4113984C2 (de) 1991-04-29 2002-05-08 Koehler Chemie Dr Franz Salze der 4-Hydroxy-Buttersäure
IT1248588B (it) * 1991-06-28 1995-01-19 Gaetano Crepaldi Composizioni farmaceutiche per la terapia dell'astinenza, del " craving", della dipendenza da sostanze stupefacenti, da sostanze psicoattive, da nicotina e dei disturbi alimentari.
ES2293638T3 (es) 1994-03-25 2008-03-16 Isotechnika, Inc. Mejora de la eficacia de farmacos por deuteracion.
US6221335B1 (en) 1994-03-25 2001-04-24 Isotechnika, Inc. Method of using deuterated calcium channel blockers
US5840331A (en) 1995-06-07 1998-11-24 Arch Development Corporation Use of γ-hydroxybutyrate for the stimulation of sleep-related secretion growth hormone and prolactin
CA2283642C (en) * 1997-03-17 2012-05-15 Btg International Limited Therapeutic compositions
US5990162A (en) 1997-08-29 1999-11-23 Orphan Medical, Inc. Method for treatment of fibromyalgia and chronic fatigue syndrome
US6440710B1 (en) 1998-12-10 2002-08-27 The Scripps Research Institute Antibody-catalyzed deuteration, tritiation, dedeuteration or detritiation of carbonyl compounds
WO2001019361A2 (en) 1999-09-14 2001-03-22 Tepha, Inc. Therapeutic uses of polymers and oligomers comprising gamma-hydroxybutyrate
US6204245B1 (en) 1999-09-17 2001-03-20 The Regents Of The University Of California Treatment of narcolepsy with immunosuppressants
PT1104760E (pt) 1999-12-03 2003-06-30 Pfizer Prod Inc Compostos de sulfamoil-heteroarilpirazole como agentes analgesicos e anti-inflamatorios
ES2383673T3 (es) * 2000-09-22 2012-06-25 Jpi Commercial, Llc Composiciones de gamma-hidroxibutirato que contienen portadores de hidrato de carbonos
AU2003280960A1 (en) 2002-07-15 2004-02-02 Alcon, Inc. Pharmaceutical compositions for otic use
TW200413273A (en) 2002-11-15 2004-08-01 Wako Pure Chem Ind Ltd Heavy hydrogenation method of heterocyclic rings
EP1934201A1 (en) 2005-10-06 2008-06-25 Auspex Pharmaceuticals Inc. Deuterated inhibitors of gastric h+, k+-atpase with enhanced therapeutic properties
US7750168B2 (en) 2006-02-10 2010-07-06 Sigma-Aldrich Co. Stabilized deuteroborane-tetrahydrofuran complex
JO2630B1 (en) 2006-04-13 2012-06-17 نوفارتيس ايه جي Organic compounds
US20080103122A1 (en) 2006-09-05 2008-05-01 Schering Corporation Pharmaceutical combinations for lipid management and in the treatment of atherosclerosis and hepatic steatosis
US20090082380A1 (en) * 2007-09-25 2009-03-26 Protia, Llc Deuterium-enriched rosuvastatin
ES2589915T3 (es) * 2008-10-08 2016-11-17 Xgene Pharmaceutical Inc Conjugados de GABA y métodos de utilización de los mismos
EP2421808B1 (en) 2009-04-23 2013-07-31 Concert Pharmaceuticals Inc. 4-hydroxybutyric acid analogs
KR101976218B1 (ko) * 2011-02-14 2019-05-07 콘서트 파마슈티컬즈, 인크. 4-히드록시부티르산 중수소화 유사체

Similar Documents

Publication Publication Date Title
JP2014513046A5 (https=)
JP7398836B2 (ja) R-ケタミンおよびその塩の医薬品としての応用
IL310501A (en) Neuroactive 19-alkoxy-17-substituted steroids, prodrugs thereof, and methods of treatment using same
JP2019520417A5 (https=)
JP2018518537A5 (https=)
JP2016534063A5 (https=)
MX2014011946A (es) Inhibidores de quinurenina-3-monooxigenasa, composiciones farmaceuticas y metodos de uso de los mismos.
JP2016510317A5 (https=)
HRP20171848T1 (hr) Upotreba malononitrilamida za neuropatsku bol
EA201071298A1 (ru) Соединение 3-аминокарбазола, фармацевтическая композиция, его содержащая, и способ их получения
JP2014502641A5 (https=)
AR082150A1 (es) N-etil-n-fenil-1,2-dihidro-4-hidroxi-5-cloro-1-metil-2-oxoquinolin-3-carboxamida deuterada, sales y usos de la misma, metodo de tratamiento, mezcla compuestos, composicion farmaceutica, proceso de preparacion, compuesto enriquecido con deuterio
JP2016513130A5 (https=)
BR112014008412A2 (pt) derivados de pirimidin-4-ona e sua utilização no tratamento, na melhora ou na prevenção de uma doença viral
RU2019141734A (ru) Терапевтические соединения и композиции и способы их применения
JP2015535247A5 (https=)
RU2017115726A (ru) Ингибиторы лизин-специфичного гингипаина
JP2011529069A5 (https=)
JP2014515407A5 (https=)
JP2018534300A5 (https=)
WO2015047982A3 (en) Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
JP2016537432A5 (https=)
RU2018146504A (ru) Лечение внутрипеченочных холестатических заболеваний
JP2022510587A5 (https=)
JP2022536160A5 (https=)